First Week Of January 2016 Options Trading For Medicines (MDCO)

Investors in Medicines Co ( MDCO) saw new options become available this week, for the January 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDCO options chain for the new January 2016 contracts and identified one put and one call contract of particular interest.

The put contract at the $19.00 strike price has a current bid of 60 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $19.00, but will also collect the premium, putting the cost basis of the shares at $18.40 (before broker commissions). To an investor already interested in purchasing shares of MDCO, that could represent an attractive alternative to paying $27.17/share today.

Because the $19.00 strike represents an approximate 30% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 86%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.16% return on the cash commitment, or 4.78% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Medicines Co , and highlighting in green where the $19.00 strike is located relative to that history:

If you liked this article you might like

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More

AveXis, Esperion and Amgen Among Biotech Movers